Onvitrelin Ucalontide

Drug Overview

Onvitrelin ucalontide (also known by its developmental code EP-100) is an investigational, recombinant fusion protein designed as a targeted membrane-disrupting agent. It consists of a luteinizing hormone-releasing hormone (LHRH) receptor-targeting ligand chemically linked to a specialized synthetic peptide known as CLIP 71.

In the clinical landscape of March 2026, onvitrelin ucalontide represents a “physical” approach to oncology, distinct from traditional chemical-based chemotherapy. It is specifically engineered to target cancer cells that overexpress LHRH receptors—a common trait in several reproductive and endocrine-related malignancies. Rather than interfering with DNA or internal cellular metabolism, this agent acts as a “molecular hole-puncher,” binding to the surface of a cancer cell and physically rupturing its outer membrane, leading to rapid cell death (lysis). This mechanism is particularly valuable because it can potentially bypass the multidrug resistance (MDR) mechanisms that often render standard treatments ineffective.

• Generic Name: Onvitrelin ucalontide.
• Code Name: EP-100.
• Drug Class: LHRH-targeted Fusion Protein; Membrane-Disrupting Peptide (MDP).
• Mechanism: Targeted binding to LHRH receptors followed by selective cell membrane disruption and osmotic lysis.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, it is not FDA-approved. It has been evaluated in Phase 1 and Phase 2 clinical trials for various gynecologic and hormone-sensitive cancers.

What Is It and How Does It Work? (Mechanism of Action)

Onvitrelin ucalontide works through a two-step “seek and destroy” process that targets the structural integrity of the cancer cell.

1. The Homing Device (LHRH Targeting)

Many types of cancer—including ovarian, breast, prostate, and endometrial cancers—display a much higher density of LHRH receptors on their surface than healthy cells.

• Specific Binding: The LHRH ligand portion of the drug acts as the “homing device,” finding and binding specifically to these receptors on the tumor cell surface. This ensures the toxic portion of the drug is delivered precisely to the malignant site.

2. The Molecular Hole-Puncher (CLIP 71)

The CLIP 71 portion is a cationic (positively charged) alpha-helical peptide.

• Electrostatic Attraction: Cancer cell membranes generally have a more negative charge than healthy cells. The positively charged CLIP 71 is naturally drawn to this negative surface.
• Membrane Rupture: Once the drug is anchored to the receptor, the CLIP 71 peptide inserts itself into the lipid bilayer of the cell membrane. This creates “pores” or holes in the membrane.

3. Rapid Cell Lysis

With its protective “skin” compromised, the cancer cell can no longer maintain its internal balance. Water rushes in, and cellular contents leak out, causing the cell to burst (lysis). Because this is a physical destruction of the cell’s structure, it is often effective even against “super-resistant” cancer cells that have learned to pump out traditional chemotherapy drugs.

Clinical Indications and Research Status (2026)

While not yet approved for general use, onvitrelin ucalontide has been a subject of research in several “LHRH-rich” malignancies:

• Recurrent Ovarian Cancer: This is the most advanced area of study. It has been evaluated in patients with platinum-resistant ovarian cancer, often in combination with other agents like paclitaxel.
• Endometrial Cancer: Investigated for its ability to target high-grade uterine tumors that overexpress LHRH receptors.
• Triple-Negative Breast Cancer (TNBC): Early-phase research has explored its utility in TNBC subtypes that lack traditional hormone receptors but still express LHRH receptors.
• Prostate Cancer: Evaluated for patients with castrate-resistant prostate cancer who have exhausted standard hormonal therapies.

Dosage and Administration Protocols

As an investigational drug, onvitrelin ucalontide dosing is strictly managed within clinical trial protocols (such as the EP-100-002 study).

Safety Profile and Side Effects

Because onvitrelin ucalontide targets receptors primarily located on the reproductive system and cancer cells, it is designed to be less toxic to the rest of the body, though some side effects are common.

Common Side Effects (>20%):

• Infusion-Related Reactions: Fever, chills, or flushing during the IV drip.
• Gastrointestinal: Mild nausea or vomiting.
• Fatigue: General systemic tiredness.

Serious Risks:

• Hormonal Changes: Because it interacts with the LHRH pathway, it can cause temporary hot flashes or changes in hormone levels.
• Injection Site Reactions: Redness or swelling at the site of the IV.
• Potential for Lysis Syndrome: In cases of extremely high tumor burden, the rapid “bursting” of cancer cells can release toxins into the bloodstream, requiring careful monitoring of kidney function.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, onvitrelin ucalontide is being used to study “Targeted Ablation.” Researchers are investigating whether this drug can be used to “clear” specific populations of diseased cells while sparing the healthy Hematopoietic Stem Cells that do not express LHRH receptors. In 2026, there is also intense focus on “Synergistic Combinations,” where the “pores” created by onvitrelin ucalontide are used as entry points for second-line chemotherapy drugs, allowing them to penetrate deep into the tumor core.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• LHRH Receptor Testing: Most clinical trials require a biopsy to confirm that the patient’s tumor expresses high levels of the LHRH receptor.
• Baseline Blood Work: Comprehensive metabolic panels to check kidney and liver function.

“Do’s and Don’ts” List:

• DO report any sudden “shivering” or “chills” during your infusion; these are often manageable with simple medications.
• DO maintain high hydration; this helps the kidneys process the fragments of cancer cells destroyed by the drug.
• DON’T ignore signs of a “hot flash” or sudden sweating, as these are expected but should be documented by your care team.
• DON’T start any new hormone-based supplements without consulting your oncologist, as they may interfere with the drug’s “homing” mechanism.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Onvitrelin ucalontide (EP-100) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and treatment options.